Nature Reviews Immunology 9, 313–323 (2009) published online 30 April 2009; corrected after print 17 July 2009
In the version of this article initially published, references for table 2 were missing. A referenced version is provided below.
References
Mimura, T. et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108–114 (2004).
Bibiloni, R. et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100, 1539–1546 (2005).
Di Giacinto, C., Marinaro, M., Sanchez, M., Strober, W. & Boirivant, M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells. J. Immunol. 174, 3237–3246 (2005).
Peran, L. et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J. Appl. Microbiol. 103, 836–844 (2007).
O'Mahony, C. et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-κB activation. PLoS Pathog. 4, e1000112 (2008).
Kruis, W. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617–1623 (2004).
Grabig, A. et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2- and Toll-like receptor 4-dependent pathways. Infect. Immun. 74, 4075–4082 (2006).
Foligne, B. et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J. Gastroenterol. 13, 236–243 (2007).
Amit-Romach, E., Uni, Z. & Reifen, R. Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis. Colon Rectum 51, 1828–1836 (2008).
Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M. & Fedorak, R. N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116, 1107–1114 (1999).
Ma, D, Forsythe, P. & Bienenstock, J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor α-induced interleukin-8 expression. Infect. Immun. 72, 5308–5314 (2004).
Schultz, M. et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm. Bowel Dis. 8, 71–80 (2002).Article
Peran, L. et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr. 97, 96–103 (2007).
Kelly, D. et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nature Immunol. 5, 104–112 (2004).
Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008).
Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731–16736 (2008).
Additional information
The online version of the original article can be found at 10.1038/nri2515
Rights and permissions
About this article
Cite this article
Round, J., Mazmanian, S. Erratum: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9, 600 (2009). https://doi.org/10.1038/nri2614
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri2614
This article is cited by
-
Precision medicine in perinatal depression in light of the human microbiome
Psychopharmacology (2020)
-
Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota
Nature Microbiology (2018)
-
Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report
Critical Care (2015)
